Table 1. Baseline patient characteristics at the first questionnaire.
| Characteristics (n = 586) | n (%) |
| Female | 414 (70.6) |
| Male | 172 (29.4) |
| Age (mean years, SD) | 59.3 (12.1) |
| Length (mean cm, SD) | 171.9 (9.4) |
| Weight (mean kg, SD) | 76.5 (14.9) |
| Concurrent autoimmune diseases | (n, %) |
| Ankylosing spondylitis | 12 (2.0) |
| Crohn’s Disease | 6 (1.0) |
| Colitis ulcerosa | 3 (0.5) |
| Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE) | 1 (0.2) |
| Sarcoidosis | 1 (0.2) |
| Scleroderma | 4 (0.7) |
| Sjögren | 1 (0.2) |
| Systemic Lupus Erythematosus | 1 (0.2) |
| Unknown | 1 (0.2) |
| Comorbidities | (n, %) a |
| Respiratory disorder | 77 (13.1) |
| Cardiovascular disorder | 172 (29.4) |
| Hypercholesterolemia | 123 (21.0) |
| Psychiatric disorder | 31 (5.3) |
| Cancer | 13 (2.2) |
| Nervous system disorder | 19 (3.2) |
| No comorbidity | 179 (30.6) |
| Not specified | 53 (9.0) |
| Smoking status | (n, %) |
| Daily | 63 (10.8) |
| Weekly | 9 (1.5) |
| Monthly or less | 21 (3.6) |
| Never | 490 (83.6) |
| Not specified | 3 (0.5) |
| RA-related comedication | (n, %) a |
| Azathioprine | 18 (3.1) |
| Hydroxychloroquine | 61 (10.4) |
| Hydrocortisone | 3 (0.5) |
| Leflunomide | 39 (6.6) |
| Methotrexate | 291 (49.5) |
| Prednisone | 78 (13.3) |
| Sulfasalazine | 38 (6.5) |
| No comedication | 123 (21.0) |
| Not specified | 32 (5.5) |
| Biological use | (n, %) |
| Abatacept (T-cell costimulation inhibitor) | 31 (5.3) |
| Adalimumab (TNF-alpha inhibitor) | 184 (31.4) |
| Anakinra (IL-1 inhibitor) | 1 (0.2) |
| Certolizumab pegol (TNF-alpha inhibitor) | 19 (3.2) |
| Etanercept (TNF-alpha inhibitor) | 262 (44.7) |
| Golimumab (TNF-alpha inhibitor) | 14 (2.4) |
| Infliximab (TNF-alpha inhibitor) | 16 (2.7) |
| Rituximab (anti-CD20) | 16 (2.7) |
| Sarilumab (IL-6 inhibitor) | 1 (0.2) |
| Secukinumab (IL-17A inhibitor) | 2 (0.3) |
| Tocilizumab (IL-6 inhibitor) | 40 (6.8) |
IL = interleukin, RA = rheumatoid arthritis; SD = standard deviation, TNF = Tumor Necrosis Factor.
aAn individual patient could have no, one or multiple comorbidities and/or comedications.